Mangoceuticals (MGRX) Liabilities and Shareholders Equity (2022 - 2026)

Mangoceuticals has disclosed Liabilities and Shareholders Equity across 5 years of filings, most recently posting $14.2 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 32.0% year-over-year to $14.2 million; the TTM figure through Jun 2026 stood at $61.2 million (down 15.83% YoY), while the FY2025 annual figure was $16.1 million, up 4.68% from the prior year.
• Liabilities and Shareholders Equity came in at $14.2 million for Q2 2026 at Mangoceuticals, down from $14.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $21.8 million in Q1 2025 to a low of $301447.0 in Q1 2024.
• Average Liabilities and Shareholders Equity over 5 years is $10.7 million, with a median of $14.4 million recorded in 2026.
• Year-over-year, Liabilities and Shareholders Equity plunged 92.67% in 2024 and surged 7116.48% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.0 million in 2022, then climbed by 4.74% to $1.1 million in 2023, then soared by 1362.75% to $15.4 million in 2024, then advanced by 4.68% to $16.1 million in 2025, then slipped by 11.91% to $14.2 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $14.2 million in Q2 2026, $14.4 million in Q1 2026, and $16.1 million in Q4 2025.